The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer drug, putting its ...

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...